FRIMOi004-A

STGD2_ FiPS4F1.7

General

Cell Line

hPSCreg name FRIMOi004-A
Cite as:
FRIMOi004-A (RRID:CVCL_UM42)
Alternative name(s)
STGD2_ FiPS4F1.7
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
RMCGENi020-A
(IPS15-00004)
Donor diseases:
Stargardt Disease
RMCGENi021-A
(IPS22-00087)
Donor diseases:
Stargardt Disease
SCTCi017-A
(IPS15-00006)
Donor diseases:
Stargardt disease
SCTCi018-A
(IPS15-00007)
Donor diseases:
Stargardt disease
FRIMOi003-A
(STGD1_ FiPS4F1.5)
Donor diseases:
Stargardt Disease
CUIMCi005-A
(BB#2, BB9068#2)
Donor diseases:
Stargardt Disease
LUMCi002-A
(113-6, LUMC0113iATAX06)
Donor diseases:
Spinocerebellar Ataxia Type 1
ZZUi030-A
(ZZU-iPS-SPG7-001)
Donor diseases:
Spastic paraplegia type 7
LUMCi002-B
(113-7, LUMC0113iATAX07)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi002-C
(113-8, LUMC0113iATAX08)
Donor diseases:
Spinocerebellar Ataxia Type 1
HDZi003-A
(hiPSC NP0038)
Donor's gene variants:
TMEM43
Donor diseases:
arrhythmogenic right ventricular dysplasia 5
FRIMOi001-A
(RP1_FiPS4F1.6)
Donor diseases:
Retinitis Pigmentosa
LUMCi055-A
(CRB1 patient 117 compound heterozygous 2983G>T p.(Glu995*) c.1892A>G, p.(Tyr631Cys), LUMC0117iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
HIHDNDi001-A
(A30P-3, SNCA3, Tue_020_A)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
HIHDNDi001-B
(A30P-4, SNCA4, Tue_020_B)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
ZZUi026-A
(ZZU-iPS-SCA3-003)
Donor diseases:
Spinocerebellar Ataxia Type 3
NUIGi027-A
(RP001C8)
Donor diseases:
Retinitis Pigmentosa
NUIGi028-A
(RP002C12)
Donor diseases:
Retinitis Pigmentosa
NUIGi029-A
(RP003C12)
Donor diseases:
Retinitis Pigmentosa
VUi011-A
(SCZ 3.5)
Donor diseases:
Schizophrenia
DHMi004-A
(HOS_1460)
Donor diseases:
Holt-Oram Syndrome
FRIMOi007-A
(PDE6C_FiPS4F1)
Donor diseases:
Achromatopsia
ZJUi009-A
(ZJULLi001-A)
Donor diseases:
Marfan Syndrome
UPITTi004-A
(CN090 C5A5J2)
Donor diseases:
Sickle cell anemia
UPITTi004-B
(CN090 C1B5B5)
Donor diseases:
Sickle cell anemia
FRIMOi006-A
(BEST1_FiPS4F1)
Donor diseases:
bestrophinopathy
AIBNi015-A
(SPG1-AU01C15)
Donor diseases:
hereditary spastic paraplegia 56
ZZUi017-A
(ZZU-iPS-SCA6-001)
Donor diseases:
Spinocerebellar Ataxia Type 6
FRIMOi002-A
(RP2_FiPS4F2.2)
Donor diseases:
Retinitis Pigmentosa
FRIMOi005-A
(RP3_FiPS4F11)
Donor diseases:
Retinitis Pigmentosa
LUMCi022-A
(115-1, LUMC0115iATAX01)
Donor diseases:
Spinocerebellar Ataxia Type 1
LUMCi022-B
(115-2, LUMC0115iATAX02)
Donor diseases:
Spinocerebellar Ataxia Type 1
Last update 24th August 2020
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Fundació de Recerca de l'Institut de Microcirurgia Ocular (FRIMO)
Owner Fundació de Recerca de l'Institut de Microcirurgia Ocular (FRIMO)
Distributors
Derivation country Spain

External Databases

Cellosaurus CVCL_UM42
BioSamples SAMEA7352795
Wikidata Q93556548

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Stargardt Disease

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

External Databases (Donor)

BioSamples SAMEA7352796

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Confirm that consent was obtained by a qualified professional Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? Yes
Details on restriction to research project Células madre como modelo de estudio para las distrofias de retina
Does consent permit unforeseen future research, without further consent? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Comité Ético de Investigación Clínica (CEIC) - Instituto de Microcirurgia Ocular
Approval number CODIMO 170505_117
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Comité Ético de Investigación Clínica (CEIC) - Instituto de Microcirurgia Ocular
Approval number CODIMO 170505_117
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Synonyms
  • fibroblast
  • Fibroblasts
  • Fibroblast
  • FIBROBLAST
show more synonyms
Source cell origin
Synonyms
  • Arm muscle

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
Unknown

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
SOX17
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
OTX2
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XY, inv(1)(p13p34)
Passage number: 12
Karyotyping method: G-Banding

Other Genotyping (Cell Line)